Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

@article{Gansevoort2016RecommendationsFT,
  title={Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice},
  author={Ron T. Gansevoort and Mustafa Arıcı and Thomas Benzing and Henrik Birn and Giovambattista Capasso and Adrian Covic and Olivier Devuyst and Christiane Drechsler and Kai-Uwe Eckardt and Francesco Emma and Bertrand Knebelmann and Yannick Le Meur and Ziad A. Massy and Albert C. M. Ong and Alberto Ortiz and Franz Schaefer and Roser Torra and Raymond C Vanholder and Andrzej Więcek and Carmine Zoccali and Wim van Biesen},
  journal={Nephrology Dialysis Transplantation},
  year={2016},
  volume={31},
  pages={337 - 348}
}
Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1–3 at initiation of treatment with evidence of rapidly progressing disease. In this paper, on behalf of the ERA-EDTA Working Groups of Inherited Kidney Disorders and European Renal Best Practice, we aim to… 

Tables from this paper

An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International

  • R. MüllerA. L. Messchendorp R. Gansevoort
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2021
TLDR
An updated algorithm to guide patient selection for treatment with tolvaptan is provided and practical advice for its use is added to incorporate new knowledge.

Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression

TLDR
The ERA-EDTA WGIKD/ERBP algorithm provides a valuable means of identifying in routine clinical practice patients who may be eligible for treatment with tolvaptan, and the impact of a new threshold for age and eGFR may increase the percentage of patients to be treated.

Clinical Manifestation and Management of ADPKD in Western Countries

TLDR
A review of advances in the management and treatment of ADPKD in Western countries found diagnostic needle aspiration and laparoscopic unroofing surgery successfully improved infection, pain, and hypertension, and peritoneal dialysis was found to be a feasible treatment for most Chinese AD PKD patients with ESRD.

Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease

TLDR
The role of genetic testing, the role of renal imaging, predicting the risk of disease progression, and pharmacological treatment options for ADPKD are focused on.

Raynaud's phenomenon triggered by the vasopressin V2 receptor antagonist tolvaptan in a patient with autosomal dominant polycystic kidney disease and Sjögren's syndrome

TLDR
Tolvaptan, a highly selective non-peptide arginine vasopressin V 2 receptor antagonist, down-regulates the total kidney volume overload and delays kidney function decline in patients with ADPKD.

Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?

TLDR
This review focuses on the rationality of tolvaptan use in pediatric patients with ADPKD, the associated challenges, and the suggested therapeutic approaches.

Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease

TLDR
Current treatment of ADPKD involves: the optimization of life style and combined pharmacological treatment with ACE inhibitors or angiotensin receptor blockers, statins and tolvaptan (patients with stage I-III CKD and rapidly progressive AD PKD).

Management of autosomal-dominant polycystic kidney disease—state-of-the-art

TLDR
The current best-practice management of ADPKD patients is reviewed with a focus on interventions that have reached clinical use to maintain kidney function and give an outlook on future trials and potential novel treatment strategies.

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

TLDR
Practical guidance is provided and steps that require consideration before and after prescribing tolvaptan to patients with ADPKD to ensure that this treatment is implemented safely and effectively are discussed.

Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease

TLDR
The MC by ultrasonography could be an option in hospitals with limited access to MRI as it performs well generally, and especially at the extremes of the MC, i.e. classes 1A, 1D and 1E.
...

References

SHOWING 1-10 OF 59 REFERENCES

Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

TLDR
This review summarized areas of consensus, gaps in knowledge, and research and health-care priorities related to diagnosis; monitoring of kidney disease progression; management of hypertension, renal function decline and complications; end-stage renal disease; extrarenal complications; and practical integrated patient support that are summarized in this review.

Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

TLDR
A post hoc analysis suggests clinically similar beneficial effects of tolvaptan in ADPKD across CKD stages 1-3 across the three phase 3 trials.

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

TLDR
Tolvaptan, as compared with placebo, slowed the increase in total kidney volume and the decline in kidney function over a 3-year period in patients with ADPKD but was associated with a higher discontinuation rate, owing to adverse events.

A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease

TLDR
This systematic review identified age and TKV as the most commonly cited prognostic indicators in the published AD PKD literature, which may inform future research, trial design and predictive models of ADPKD natural history, helping to optimise patient care.

Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry.

  • E. M. SpithovenA. Kramer R. Gansevoort
  • Medicine, Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2014
TLDR
In ADPKD patients on RRT, survival has improved markedly, especially due to a decrease in cardiovascular mortality, which has led to a considerable increase in the number of AD PKD patients being treated with RRT.

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

TLDR
Although hepatocellular injury following long-term tolvaptan treatment in ADPKD subjects was infrequent and reversible, the potential for serious irreversible injury exists and regular monitoring of transaminase levels is warranted in this patient population.

The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.

TLDR
A new prognostic score accurately predicts renal outcomes in patients with AD PKD and may enable the personalization of therapeutic management of ADPKD.

Polycystic kidney disease: a 2011 update

  • T. Steinman
  • Medicine
    Current opinion in nephrology and hypertension
  • 2012
TLDR
Assessing total kidney volume and noting its relationship to glomerular filtration rate is key in predicting the course of the disease and will aid in the evaluation of the new research initiatives that are designed to stop cyst proliferation and fluid secretion into the kidney cysts.

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.

TLDR
D doses of tolvaptan typically used in patients with ADPKD do not produce a difference in renal hemodynamic profile in chronic kidney disease stages 1 through 4, but minor GFR drops may be observed in individual patients.

Imaging for the prognosis of autosomal dominant polycystic kidney disease

TLDR
The overwhelming evidence in support of the view that imaging is an invaluable tool to monitor the onset and progression of ADPKD and is well-suited to gauge the response of this disease to targeted therapy before renal function begins to decline is discussed.
...